Related Experiment Video
Updated: Jun 5, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Ceftobiprole Medocaril: A New Fifth-Generation Cephalosporin
Justin Zimmerman1, Christopher Giuliano1,2, Pramodini B Kale-Pradhan1,2
1Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA.
Ceftobiprole shows efficacy in treating bloodstream infections, skin infections, and community-acquired pneumonia. While generally safe, its effectiveness in hospital-acquired pneumonia requires further investigation.
Area of Science:
- Pharmacology and Therapeutics
- Infectious Diseases
- Clinical Trials
Background:
- Limited treatment options exist for multidrug-resistant bacterial infections.
- Intravenous ceftobiprole offers broad-spectrum antimicrobial activity.
Purpose of the Study:
- To review the pharmacology, efficacy, and safety of intravenous ceftobiprole.
- To evaluate its use in bloodstream infections, ABSSSIs, CAP, HAP, and VAP.
Main Methods:
- Searched PubMed and ClinicalTrials.gov for ceftobiprole-related studies.
- Reviewed English articles published from January 1985 to August 2024.
Main Results:
- Ceftobiprole demonstrated comparable efficacy to comparators in CAP, ABSSSIs, and bacteremia.
- Treatment success rates were high for ceftobiprole in these indications.
- Efficacy was inferior in the ventilator-associated pneumonia (VAP) population.
- A favorable safety profile was observed, with gastrointestinal events being more frequent.
Conclusions:
- Ceftobiprole is a viable option for hospitalized patients with CAP, ABSSSI, and methicillin-resistant Staphylococcus aureus bacteremia.
- Further research is needed for its use in severe HAP/VAP, febrile neutropenia, and pediatric populations.
More Related Videos
11:15Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Related Concept Videos
Antimicrobial Effectiveness
Antibiotic Selection
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Carboxylic Acid Derivatives: Overview
Crown Ethers
Chemical Agents for Microbial Control